Evidence map›Paper›PMID 42635242›Full record

ArticleBioinformatics (Oxford, England)2026

De novo epitope-specific antibody design via time-dependent guidance.

Yunji Kim, Minkyung Baek

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yunji KimInterdisciplinary Program in Artificial Intelligence, Seoul National University, Seoul 08826, Republic of Korea.
Minkyung BaekInterdisciplinary Program in Artificial Intelligence, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0000-0003-3414-9404

Funding

Institute of Information & Communications Technology Planning & Evaluation RS-2021-II211343Institute of Information & Communications Technology Planning & Evaluation RS-2025-02653113Institute of Information & Communications Technology Planning & Evaluation RS-2025-25442149Korea Basic Science Institute RS-2024-00401698Korea governmentNational Research Foundation of Korea RS-2024-00397865
6 · The paper itself

Abstract

motivationDe novo antibody design requires jointly determining the global binding orientation and shaping flexible CDR loops to engage a target epitope. Diffusion-based approaches such as RFantibody are capable of this joint task but frequently produce severe steric clashes requiring extensive post-hoc filtering. Flow-based methods such as IgFlow and FlowDesign offer more stable generation but remain restricted to pre-aligned frames, precluding true de novo design. Achieving structural integrity and epitope specificity simultaneously in this setting remains an open challenge.

resultsWe propose TiDE-Ab, a conditional SE(3) flow matching framework for de novo epitope-specific antibody design. By conditioning on unpaired antigen and antibody structures without any pre-aligned frame, TiDE-Ab inherits the structural stability of flow matching while enabling global binding pose search from scratch. To further improve epitope targeting, we introduce Time-Dependent Classifier-Free Guidance (TD-CFG), which replaces static conditioning with an adaptive schedule: strong guidance early to establish the global binding pose, followed by gradual relaxation for precise local CDR refinement. On 55 non-redundant benchmark complexes, TiDE-Ab outperforms RFantibody with higher epitope recall (0.935 vs. 0.878) and over 95% fewer steric clashes. In therapeutic case studies on TGF-β and IL-17A, TiDE-Ab reproduced the binding profiles of clinical antibodies across isoform-selective and cross-reactive epitopes, whereas RFantibody consistently failed to produce viable candidates. AVAILABILITY: Source code, data, and trained models are available at https://github.com/SNU-CSSB/TiDE-Ab.

Indexed as

AntibodiesEpitopesProtein EngineeringAntibodiesEpitopes

Identifiers

PMID42635242
PMCPMC13501287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.